阿科力：10月24日召开董事会会议

Group 1 - Acolyte (SH 603722) announced the convening of its fifth board meeting on October 24, 2025, to review the proposal for the third quarter report of 2025 [1] - For the year 2024, Acolyte's revenue composition is 99.84% from chemical products and 0.16% from other businesses [1] - As of the report, Acolyte's market capitalization stands at 3.9 billion yuan [1] Group 2 - The Chinese innovative drug sector has generated $80 billion in overseas licensing deals this year [1] - The secondary market for biomedicine is experiencing a surge, while the primary market is facing challenges in fundraising [1]